Perspectives of CB1 antagonist in treatment of obesity: Experience of RIO-Asia

Journal of Obesity

Volumn 2011, Issue , 2011, Pages

  Pan, Changyu ^a   Yoo, Hyung Joon ^b   Ho, Low Tone ^c,d  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b Hangang Sacred Heart Hospital   (South Korea)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053238812     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2011/957268     Document Type: Article

References (38)

1. Global activity on diet, physical activity and health; obesity and overweight. WHO 2008, http://www.who.int/dietphysicalactivity/publications/ facts/obesity/en/
2. Wu Y., Overweight and obesity in China. British Medical Journal 2006 333 7564 362 363 2-s2.0-33747587290 (Pubitemid 44298059)
3. Chu N. F., Prevalence of obesity in Taiwan. Obesity Reviews 2005 6 4 271 274 2-s2.0-27744436900 10.1111/j.1467-789X.2005.00175.x (Pubitemid 41581636)
4. Kim D. M., Ahn C. W., Nam S. Y., National prevalence of obesity: prevalence of obesity in Korea. Obesity Reviews 2005 6 2 117 121 2-s2.0-18044362517 10.1111/j.1467-789X.2005.00173.x (Pubitemid 40604420)
5. Herling A. W., Kilp S., Elvert R., Haschke G., Kramer W., Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 2008 149 5 2557 2566 2-s2.0-42449164329 10.1210/en.2007-1515 (Pubitemid 351574492)
6. Sonnenberg G. E., Krakower G. R., Kissebah A. H., A novel pathway to the manifestations of metabolic syndrome. Obesity Research 2004 12 2 180 186 2-s2.0-2942698938 (Pubitemid 41132540)
7. Poirier P., Giles T. D., Bray G. A., Hong Y., Stern J. S., Pi-Sunyer F. X., Eckel R. H., Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 5 968 976 2-s2.0-33646448307 10.1161/01.ATV.0000216787. 85457.f3 (Pubitemid 43732100)
8. Ohnishi H., Saitoh S., Akasaka H., Mitsumata K., Chiba M., Furugen M., Furukawa T., Mori M., Shimamoto K., Incidence of hypertension in individuals with abdominal obesity in a rural Japanese population: the Tanno and Sobetsu study. Hypertension Research 2008 31 7 1385 1390 2-s2.0-55449117250 10.1291/hypres.31.1385
9. Vgontzas A. N., Papanicolaou D. A., Bixler E. O., Hopper K., Lotsikas A., Lin H. M., Kales A., Chrousos G. P., Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. Journal of Clinical Endocrinology and Metabolism 2000 85 3 1151 1158 2-s2.0-0034455007 10.1210/jc.85.3.1151 (Pubitemid 32269364)
10. Sun H. J., Ji E. Y., Eun J. P., Body mass index and cancer risk in Korean men and women. International Journal of Cancer 2008 123 8 1892 1896 2-s2.0-51949098299 10.1002/ijc.23719
11. Akbas F., Gasteyger C., Sjödin A., Astrup A., Larsen T. M., A critical review of the cannabinoid receptor as a drug target for obesity management. Obesity Reviews 2009 10 1 58 67 2-s2.0-58149214108 10.1111/j.1467-789X.2008.00520.x
12. Bronander K. A., Bloch M. J., Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. Vascular Health and Risk Management 2007 3 2 181 190 2-s2.0-34249849860 10.2147/vhrm.2007.3.2.181 (Pubitemid 46860707)
13. Shire D., Calandra B., Delpech M., Dumont X., Kaghad M., Le Fur G., Caput D., Ferrara P., Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. Journal of Biological Chemistry 1996 271 12 6941 6946 2-s2.0-0029965292 10.1074/jbc.271.12.6941 (Pubitemid 26104790)
14. Bifulco M., Grimaldi C., Gazzerro P., Pisanti S., Santoro A., Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Molecular Pharmacology 2007 71 6 1445 1456 2-s2.0-34347336599 10.1124/mol.106.033118 (Pubitemid 47010897)
15. Quarta C., Bellocchio L., Mancini G., Mazza R., Cervino C., Braulke L. J., Fekete C., Latorre R., Nanni C., Bucci M., Clemens L. E., Heldmaier G., Watanabe M., Leste-Lassere T., Maitre M., Tedesco L., Fanelli F., Reuss S., Klaus S., Srivastava R. K., Monory K., Valerio A., Grandis A., De Giorgio R., Pasquali R., Nisoli E., Cota D., Lutz B., Marsicano G., Pagotto U., CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metabolism 2010 11 4 273 285 2-s2.0-77950199353 10.1016/j.cmet.2010.02.015
16. Gary-Bobo M., Elachouri G., Gallas J. F., Janiak P., Marini P., Ravinet-Trillou C., Chabbert M., Cruccioli N., Pfersdorff C., Roque C., Arnone M., Croci T., Soubrié P., Oury-Donat F., Maffrand J. P., Scatton B., Lacheretz F., Le Fur G., Herbert J. M., Bensaid M., Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats. Hepatology 2007 46 1 122 129 2-s2.0-34547423962 10.1002/hep.21641 (Pubitemid 47171928)
17. Di Marzo V., The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacological Research 2009 60 2 77 84 2-s2.0-67449119913 10.1016/j.phrs.2009.02.010
18. Van Gaal L. F., Rissanen A. M., Scheen A. J., Ziegler O., Rössner S., Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 365 9468 1389 1397 2-s2.0-17144382751 10.1016/S0140-6736(05)66374-X (Pubitemid 40523733)
19. Pi-Sunyer F. X., Aronne L. J., Heshmati H. M., Devin J., Rosenstock J., Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients-RIO-North America: a randomized controlled trial. Journal of the American Medical Association 2006 295 7 761 775 2-s2.0-32644441249 10.1001/jama.295.7.761 (Pubitemid 43244304)
20. Després J. P., Golay A., Sjöström L., Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine 2005 353 20 2121 2134 2-s2.0-27844463517 10.1056/NEJMoa044537 (Pubitemid 41653104)
21. Levine J. A., Obesity in China: causes and solutions. Chinese Medical Journal 2008 121 11 1043 1050 2-s2.0-50549083305
22. Kim Y., Youn K. S., Choi H., BMI and metabolic disorders in South Korean adults: 1998 Korea National Health and Nutrition Survey. Obesity Research 2004 12 3 445 453 2-s2.0-3042668576 (Pubitemid 41132523)
23. Barba C., Cavalli-Sforza T., Cutter J., Darnton-Hill I., Deurenberg P., Deurenberg-Yap M., Gill T., James P., Ko G., Nishida C., Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004 363 9403 157 163 2-s2.0-0347948541 10.1016/S0140- 6736(03)15268-3 (Pubitemid 38068335)
24. Chang C.-J., em75210@email.ncku.edu.tw Wu C.-H., Chang C.-S., Yao W.-J., Yang Y.-C., Wu J.-S., Lu F.-H., Low body mass index but high percent body fat in Taiwanese subjects: implications of obesity cutoffs. International Journal of Obesity 2003 27 2 253 259 10.1038/sj.ijo.802197 (Pubitemid 36255809)
25. World Health Organization Western Pacific Region, International Association for the Study of Obesity and International Obesity Task Force, The Asia-Pacific perspective: redefining obesity and its treatment. Australia: Health Communications Australia Pty Limited, 2000
26. van der Kooy K., Seidell J. C., Techniques for the measurement of visceral fat: a practical guide. International Journal of Obesity 1993 17 4 187 196 (Pubitemid 23133348)
27. Balkau B., Deanfield J. E., Després J. P., Bassand J. P., Fox K. A. A., Smith S. C., Barter P., Tan C. E., Van Gaal L., Wittchen H. U., Massien C., Haffner S. M., International day for the evaluation of abdominal obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168 000 primary care patients in 63 countries. Circulation 2007 116 17 1942 1951 2-s2.0-37349066531 10.1161/CIRCULATIONAHA.106.676379 (Pubitemid 350287090)
28. Gallagher D., Overweight and obesity BMI cut-offs and their relation to metabolic disorders in Koreans/Asians. Obesity Research 2004 12 3 440 441 2-s2.0-3042666234 (Pubitemid 41132521)
29. Pan W. H., Flegal K. M., Chang H. Y., Yeh W. T., Yeh C. J., Lee W. C., Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. American Journal of Clinical Nutrition 2004 79 1 31 39 2-s2.0-12344337734 (Pubitemid 41132059)
30. Christensen R., Kristensen P. K., Bartels E. M., Bliddal H., Astrup A., Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007 370 9600 1706 1713 2-s2.0-36048995288 10.1016/S0140-6736(07)61721-8 (Pubitemid 350100788)
31. Scheen A. J., CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. Journal of Neuroendocrinology 2008 20 supplement 1 139 146 2-s2.0-42449151676 10.1111/j.1365-2826.2008.01681.x (Pubitemid 351559287)
32. Janero D. R., Makriyannis A., Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs 2009 14 1 43 65 2-s2.0-65649122618 10.1517/14728210902736568
33. Storr M. A., Sharkey K. A., The endocannabinoid system and gut-brain signalling. Current Opinion in Pharmacology 2007 7 6 575 582 2-s2.0-36549015066 10.1016/j.coph.2007.08.008 (Pubitemid 350177551)
34. LoVerme J., Duranti A., Tontini A., Spadoni G., Mor M., Rivara S., Stella N., Xu C., Tarzia G., Piomelli D., Synthesis and characterization of a peripherally restricted CB cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorganic and Medicinal Chemistry Letters 2009 19 3 639 643 2-s2.0-58849116267 10.1016/j.bmcl.2008.12.059
35. Posner K., Oquendo M. A., Gould M., Stanley B., Davies M., Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. American Journal of Psychiatry 2007 164 7 1035 1043 2-s2.0-34249333702 10.1176/appi.ajp.164.7.1035 (Pubitemid 47121392)
36. Wu C. H., Hung M. S., Song J. S., Yeh T. K., Chou M. C., Chu C. M., Jan J. J., Hsieh M. T., Tseng S. L., Chang C. P., Hsieh W. P., Lin Y., Yeh Y. N., Chung W. L., Kuo C. W., Lin C. Y., Shy H. S., Chao Y.U.S., Shia K. S., Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H- pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice. Journal of Medicinal Chemistry 2009 52 14 4496 4510 2-s2.0-67650714102 10.1021/jm900471u
37. Receveur J. M., Murray A., Linget J. M., Nørregaard P. K., Cooper M., Bjurling E., Nielsen P. A., Högberg T., Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier. Bioorganic and Medicinal Chemistry Letters 2010 20 2 453 457 2-s2.0-72249112327 10.1016/j.bmcl.2009.12.003
38. Tam J., Vemuri V. K., Liu J., Bátkai S., Mukhopadhyay B., Godlewski G., Osei-Hyiaman D., Ohnuma S., Ambudkar S. V., Pickel J., Makriyannis A., a.makriyannis@neu.edu Kunos G., gkunos@mail.nih.gov Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. Journal of Clinical Investigation 2010 120 8 2953 2966 10.1172/JCI42551